Patients with concurrent risk scores tended to have higher tumor grade, IDH-wild type, and no 1p/19q co-deletion, which was consistent with previous studies [51,52] and more suggestive of a high-risk adverse prognostic profile. This evidence concerns the gene IDH1 and neoplasm.